Clinical research

Trust launches a new clinical trial for cystic fibrosis patients

Royal Papworth Hospital NHS FT has launched phase II of the clinical trial for patients with cystic fibrosis with serious lung infections, such as Mycobacterium abscessus. The trial aims to reduce the amount of mycobacteria, by using a solution which releases nitric oxide into the upper airways and deep alveolar spaces of the lungs. The method is to help kill viruses and bacteria and boost a person’s immune response.

Clinical trials are expected to start soon – with the nebulised nitric oxide generating solution (RESP301) - administered via a handheld nebuliser. Laboratory testing has shown strong activity against many bacterial species including M. abscessus, as well as viruses such as various influenza and coronavirus strains. 

The study – known as NOMAB – will treat patients with RESP301 over a 28-day period, aiming to measure the changes in the amount of mycobacteria in the lungs before and after treatment. It will also analyse whether there are any improvements in lung function.

Professor Andres Floto, the Research Director of the Cambridge Centre for Lung Infection (CCLI), Professor of Respiratory Biology at the University of Cambridge, and co-chief investigator for the study, said: “Infection with M. abscessus is a major problem for people with cystic fibrosis, is very difficult to treat, leads to accelerated lung damage, and can prevent safe lung transplantation.”

Dr Charles Haworth, co-chief investigator for the study and a respiratory consultant at the CCLI at the trust, added: “Lung infections in people with cystic fibrosis are becoming harder to treat due to the increasing prevalence of multi-drug resistant organisms such as M. abscessus. We urgently need new and effective approaches to combat these infections.”

There will initially be 12 subjects recruited, and if successful, expanded to a larger trial, broadening the scope of RESP301 in cystic fibrosis and other lung conditions. 

The study will be conducted at the trust, one of the UK’s leading centres for cystic fibrosis.

NHE Sept/Oct 21

NHE Sept/Oct 21

Improving care for long-term conditions

Join us in our September/October edition of National Health Executive, as we explore a range of topics impacting and improving the care that we can deliver to patients, the facilities within which we deliver them, and the opportunities in the digital space to accent and evolve our care capabilities


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Digital Healthcare

The integration of new technology, such as using virtual outpatient appointments instead of face-to-face reviews of patients in the hospital. Adapting the ways in which our NHS workers serve people has been critical in continuing to provide high-quality treatment, a positive patient experience and preventing Covid-19 transmission during the pandemic. Our healthcare sector has the potential to transform the way we continue to provide essential services while also improving patient care. But how easy is the integration of these innovations into routine NHS practice?

On the 28th of October, at the NHE365 Virtual Hospitals & Technology Enabled Care online event, we will be discussing patient flow and experience, reducing waiting times, reducing the patient backlog and increasing technology adoption. Will you be attending? 

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all